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In healthy subjects octreotide is largely metabolised
by the liver suggesting that the plasma half-life of the
somatostatin analogue may be prolonged in patients
with hepatic dysfunction. The aim of this study was
therefore (a) to determine the pharmacokinetics of
octreotide following its subcutaneous injection in 6
patients with cirrhosis and portal hypertension and
(b) compare the magnitude and duration of the effects
of intravenous administration of 250 Ig somatostatin
and 50g octreotide on corrected wedged hepatic
venous pressure (WHVP) and to relate the findings to
the plasma levels of the analogue lh after adminis-
tration in 13 patients with cirrhosis and portal
hypertension. Following subcutaneous administra-
tion of 50g octreotide the circulating half life(range
2.4 to 4.79 h) was prolonged whereas the clearance
(range 2.101 to 4.775 L/h) was decreased compared to
healthy controls. Intravenous bolus administration of
250g somatostatin or 50g octreotide resulted in a
reduction in WHVP of approximately the same
magnitude and duration despite appreciable quan-
tities of the analogue in the blood lh after admin-
istration (1944 +-. 226 pg/ml). These results indicate
that the circulating half-life of octreotide is pro-
longed in cirrhotic8 suggesting that the dosage
regimens should be modified in such patients to
avoid accumulation of the analogue in the blood
which may result in undesirable side-effects or
toxicity. Furthermore, since the magnitude and
duration of the reduction in WHVP elicited by IV
octreotide is similar to that obseved with somatosta-
tin, the analogue, like the native hormone, must be
administered by continuous IV infusion to produce a
sustained response and hence a therapeutic effect in
the management of acute variceal bleeding.
Keywords: Pharmacokinetics, octreotide, somatostatin, cir-
rhosis, wedged hepatic venous pressure
INTRODUCTION
Somatostatin, a naturally occuring 14-amino
acid peptide has a plethora of effects on gas-
trointestinal function leading to the suggestion
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that it might have a therapeutic role in a variety
of gastrointestinal indications. However, since
somatostatin has a short half-life (1-2mins).[1]
and requires intravenous administration to
maintain therapeutic levels, longer acting analo-
gues have been developed. Octreotide, one such
analogue, is an octapeptide in which the 4 amino
acid sequence essential for the biological activity
of the native hormone is retained. However,
incorporation of N-terminal phenyalanine, C-
terminal amino alcohol, D-tryptophan and a
cysteine bridge makes the molecule very
resistant to metabolic degration [2, 3] and conse-
quently, octreotide has a much longer circulat-
ing half-life than somatostatin in healthy
volunteers [4, 5]. In normal healthy volunteers
octreotide is largely metabolised by the liver, the
hepatic excretion being in the order of 30-40%
[5]. No data is available on the plasma half-life of
octreotide in cirrhotic patients but it is reason-
able to assume that the hepatic extraction is
reduced according to the degree of liver dys-
function and that the circulating half-life is likely
to be prolonged compared to normal subjects.
Consequently, the relationship between dosage
regimens and the clinical effects of octreotide
are likely to be different in cirrhotic patients
compared to healthy volunteers. Since interest
is accumulating in the use of octreotide for the
control of the acute variceal hemorrhage and in
the long-term management of portal hyperten-
sion, we have investigated the circulatory half-
life of octreotide following its subcutaneous
administration in cirrhotics. Furthermore, we
also studied the relationship between the mag-
nitude and duration of response of octreotide
on corrected wedged hepatic venous pressure
(WHVP) and the circulating levels ofthe analogue
after intravenous administration.
Subcutaneous Administration of Octreotide
Six patients (4 males and 2 females), receiving
50tg octreotide s.c. twice daily to prevent
recurrent varieceal hemorrhage were studied 4
weeks after commencing treatment with the
analogue. These patients were participating in
a randomised controlled trial and had already
undergone a baseline measurement of corrected
wedged hepatic venous pressure (WHVP) prior
to being commenced on octreotide (50 tg.sc.bd).
Furthermore, since all patients were scheduled
to have their WHVP measured at the end of
study (six months), it was considered unethical
to subject them to a further haemodynamic
investigation four weeks into the trial. Since
octreotide administered subcutaneously acts as
a slow release preparation, there is no informa-
tion on the temporal relationships between the
time of administration and the reductions in
corrected WHVP in patients already receiving
the analogue. Consequently, it would not have
been practical to measure corrected WHVP
for the duration of this part of the study (12h).
One patient had severe (Child’s C), 2 moderate
(Child’s B) and 3 mild (Child’s A) liver dys-
function. Following an overnight fast, blood
samples were removed immediately prior to a
subcutaneous injection of 50tg octreotide and
then at 2 hourly intervals for the following 12 h.
The blood samples were collected in hepari-
nised bottles containing Trasylol, centrifuged
at 0C, the plasma snap frozen and stored at
-20C for subsequent analysis of the octreo-
tide levels.
INTRAVENOUS ADMINISTRATION
OF OCTREOTIDE
MATERIALS AND METHODS
This study was approved by the Royal Liverpool
University Hospital Ethical Committee and all
patients gave written informed consent.
Thirteen patient with cirrhosis and portal hy-
pertension admitted for a thorough investigation
of the etiology and severity of their liver disease
underwent measurements of their corrected
wedged hepatic venous pressure (WHVP).PHARMACOKINETICS OF OCTREOTIDE 15
Two introducer sheaths (Cordis 8F, Cordis
Corporation, Miami, USA) were inserted into
the right femoral vein under local anaesthesia. A
7F occlusion ballon Sidewinder catheter (Cordis
Corporation, Miami, USA) was guided into a
hepatic vein under fluoroscopic control. With
the ballon inflated, confirmation of wedging was
obtained by the absence of the reflux into the
inferior vena cava following the injection of 2ml
of intravenous contrast. A straight 7F Cordis
catheter was inserted into the femoral vein via
the second introducer and guided under fluoro-
scopic control until its tip lay free in the inferior
vena cava (IVC) at the level of the ballon catheter
for the measurement of free hepatic vein
pressure. The right femoral artery was cannu-
lated with a 7F Cordis cannula via a 8F Cordis
introducer. Pressure were recorded with iso-
lated Medex 860 transducers (Medex Medical
Inc. Rossendale, UK) connected via amplifiers
to an Electromed multichannel chart recorder
(Electromed UK Ltd., Letchworth, Herts, UK).
The midchest region was chosen as the zero
level for transducer calibration. Corrected
wedged hepatic venous pressure was calculated
by subtracting the free pressure (IVC catheter)
from the wedged (balloon catheter). Using two
catheters allowed continuous measurement of
wedged and free hepatic venous pressures
during administration of the vasoactive drugs
or saline. When not being used to measure
wedged hepatic venous pressure the balloon of
the Sidewinder catheter was deflated and the
catheter withdrawn 1-2 cm. The free pressure
measurements obtained from both catheters
were compared to ensure that the inferior cava
pressure measurements were representative
of the free wedged hepatic venous pressure.
The Sidewinder catheter was then reintroduced
into the hepatic vein, the balloon inflated and
confirmation of wedging reconfirmed as de-
scribed above.
Heart rate was recorded using a pressure
sensitive cuff connected to a Cardiocaps monitor
(Dataex Ltd, Helsinki, Finland).
A small catheter was introduced into an
antecubital vein for the administration of the
vasoactive drugs or saline. Ideally, the best
exPerimental design would have been to ran-
domise the administrations of somatostatin and
octreotide in a double-blind manner. However,
at the time of study we expected octreotide to
have a prolonged duration of action on hepatic
haemodynamics and therefore we considered it
was not practical to administer the drugs in a
double-blind randomised fashion. Conse-
quently, all patients received bolus injections of
saline, 250 tg somatostatin, saline, 50 tg octreo-
tide and saline consecutively, all in a volume of
2 ml. All injections were given 10 min after the
haemodynamic parameters had stabilised fol-
lowing the previous administration of saline or
vasoactive drug and during this period the
balloon on the Sidewinder catheter was deflated.
The patients were unaware of whether or not
they were receiving saline, somatostatin or
octreotide. The magnitude and duration of the
effects of somatostatin, octreotide and saline on
wedged and free hepatic venous pressures,
arterial blood pressure and heart rate were
recorded.
One hour after completion of the investiga-
tions a blood sample was removed from all
patients and stored for subsequent determina-
tion of octreotide levels.
Analytical Methods
The concentration of octreotide in the plasma
samples was measured using a specific radio-
immunoasay (Sandoz Pharmaceuticals, Basle,
Switzerland) as previously described [5]. The
sensitivity of the assay was 5 pg/ml, the cross
reactivity with somatostatin less than 0.01% and
the intra- and inter-assay coefficients less than
10%. The plasma half-life of octreotide was
calculated by linear regression over the period
2-12h after administration. The area under
the curve (AUC) 2-12 h after administration of
octreotide was calculated by the Trapezoidal16 S.A. JENKINS et al.
rule correcting for the declining basal levels by
subtracting Co/K and for the AUC 2-12 h by
subtracting C12/K where:-
Co and C12=concentrations at times 0 and 12 h
0.693 0.693 K= tl/2 T1/2
These allowances used to calculate the AUC
virtually cancel each other indicating a steady
state. Clearance (CL) was derived from Dose/
AUC 2-12 h and the volume of distribution (Vd)
from CL/K.
Statistical Analysis
Differences in corrected WHVP levels before
and after administration of somatostatin, octreo-
tide and saline were evaluated using a Mann
Whitney test for paired data.
RESULTS
Subcutaneous Administration of Octreotide
All patients had been receiving 50 tg octreotide
s.c.b.d, for 4 weeks with the last injection being
administered 12 h prior to commencement of the
study. Consequently, all patients had detectable
baseline levels of octreotide in the plasma
immediately prior to the s.c. injection of 50 tg
of the analogue for the pharmacokinetic study.
Furthermore, the baseline octreotide levels were
highest in the patient with severe hepatic
dysfunction and lowest in the 3 with good liver
function (Tab. I).
Peak plasma concentrations of octreotide were
observed 2 h after subcutaneous administration
TABLE Baseline and peak plasma levels of octreotide in
the 6 patients participating in the pharmacokinetic study
Patient Child’s grade Plasma octreotide levels (pg/ml)
Basal Peak
A 148 2588
2 A 88 2198
3 A 178 2092
4 B 396 2942
5 B 720 3276
6 C 1195 3511
of 50 tg octreotide and thereafter declined in all
patients. The lowest peak levels of octreotide
were observed in patients with good liver
function and the highest in the one patient with
severe hepatic dysfunction (Tab. I). The plasma
half-life of octreotide in the 6 patients was
variable (range 2.4 to 4.89 h) being appreciably
shorter in patients with good liver function
than those with moderate or severe hepatic dys-
function (Tab. II). Nevertheless, overall, the
plasma half-life of octreotide in the six patients
(3.44 4-1.01 h; mean 4- SD) was increased and the
clearance decreased (3.04 4- 0.9 L/h mean 4- SD)
compared to those previously reported for
normal healthy subjects [5].
Intravenous Administration of Octreotide
and Somatostatin
Approximately 15-20 seconds after intravenous
bolus administration of either 250tg soma-
tostatin or 50tg octreotide, wedged and
corrected wedged hepatic venous pressure
began to decrease, the maximum reductions
being observed approximately 50-60 seconds
after administration of both drugs (Tab. III).
Thereafter, both wedged and corrected wedged
TABLE II Pharmacokinetic variables of octreotide (50g s.c.) in six patients with cirrhosis and portal hypertension
Patient Child’s grade 1/2 (h) K (h-1) AUC (ng/ml.h) Clearance (L/h) Volume of distribution (L)
1 A 2.40 0.271 10.47 4.775 17.62
2 A 2.76 0.251 17.21 2.892 11.51
3 A 2.56 0.288 16.55 3.021 10.47
4 B 4.03 0.172 18.08 2.765 16.07
5 B 4.04 0.172 18.49 2.704 15.77
6 C 4.89 0.142 23.79 2.101 14.82PHARMACOKINETICS OF OCTREOTIDE 17
TABLE III The effects and duration of action of somatostatin, octreotide and saline on hepatic venous pressure, mean arterial
blood pressure and pulse in 13 patients with cirrhosis and portal hypertension
Saline Somatostatin Saline Octreotide Saline
Before After Before After Before After Before After Before After
Wedged hepatic
venous pressure
(mm Hg)
Free hepatic
venous pressure
(mm Hg)
Corrected hepatic
venous pressure
(mm Hg)
Mean arterial
blood pressure
(mm Hg)
Pulse
beats (min)
Duration of hepatic
venous response
(min)
31.6+1.9 32.1+1.9 31.6+1.8 27.2+1.7"* 31.5+2.0 31.7+2.0 31.8+1.8 29+2.1" 31.6+1.8 31.8+1.9
8.4+1.8 8.7+1.9 8.3+1.6 8.6+1.8 8.4+1.6 8.4+1.7 8.4+1.9 8.6+1.7 8.5+1.8 8.6+1.9
23.1+1.5 23.4+1.7 23.3+1.8 18.6+1.8"* 23.1+1.9 23.3+1.8 23.4+1.7 18.4+1.5"* 23.1+1.6 23.2+1.5
103+5 104+4 105+4 121+8" 103+4 102+5 101+4 115+5" 102+5" 103+4
75+3 76+4 78+3 65+3* 75+4 75+4 76+3 63+3* 77+3 76+4
1.9+0.4 2.3+0.6
Results are expressed as mean + SEM.
*p < 0.01.
**p < 0.001.
The changes shown after administration of somatostatin, octreotide and saline are the maximal responses from the baseline for each patient.
hepatic venous pressures began to increase.
Thus, somewhat surprisingly there was no
significant difference in the duration of the
reduction of wedged or corrected wedged
hepatic venous pressures following somatoatin
or octreotide administration (Tab. III), despite
the presence of appreciable amounts of octreo-
tide in the plasma (1944 4-226 pg/ml) one hour
after administration. Saline administered before,
between or following the administration of
somatostatin and octreotide had no significant
effect on wedged or corrected wedged hepatic
venous pressures.
Between administrations of somatostatin, oc-
treotide and saline when the balloon was
deflated and the Sidewinder catheter withdrawn
from the wedged position, there was excellent
agreement between the free pressures recorded
from this catheter and the other lying free in the
inferior cava, the differences in the readings not
exceeding 0.2mm Hg. Somatostatin, octreotide
and saline had no significant effect on the free
hepatic venous pressure.
Approximately 30-40 seconds after intra-
venous bolus administration of either 250tg
somatostain or 50tg octreotide mean arterial
pressure began to increase, the maximal re-
sponse occurring 70-80 seconds after adminis-
tration of both drugs (Tab. III). Thereafter,
arterial pressure began to decrease. There was
no significant difference in the duration of the
increase in mean arterial blood pressure follow-
ing somatostatin (2.1 4-0.6 min) or octreotide
(2.34-0.5 min) administration. Saline had no
effect on arterial blood pressure (Tab. III).
Forty to fifty seconds after intravenous
administration of 250 tg somatostatin or 50 tg
octreotide, the heart rate began to decrease, the
maximum reduction occurring approximately
80-90 seconds after administration of both
drugs (Tab. III). Thereafter, the pulse rate began
to return to normal. There was no significant
difference in the duration of the bradycardia
following somatostatin (2.0 4- 0.6 min) or octreo-
tide (2.3 4- 0.5 min) administration. Saline had no
significant effect on the pulse rate (Tab. III). No18 S.A. JENKINS et al.
major side effects of somatostatin or octreotide
were observed in this study.
DISCUSSION
The results of this study demonstrate that
following subcutaneous administration the plas-
ma half-life of octreotide is increased and the
clearance decreased in cirrhotic patients com-
pared to those previously reported for normal
healthy controls [4, 5] using the same radio-
immunoassay kit. Furthermore, there appeared
to be a considerable variation in the plasma half-
life of octreotide in cirrhotic patients according
to the severity of the liver disease. Thus in
cirrhotics with severe (Child’s C) or moderate
(Child’s B) hepatic dysfunction the plasma half-
life of octreotide was appreciably longer than in
patients with mild disease (Child’s A), although
the small number of patients studied limits any
definitive conclusions. These observations are
perhaps not unexpected since the liver is the
principal site for the elimination of octreotide,
the hepatic excretion being estimated to be
between 30-40% in normal healthy volunteers
[5]. Consequently it is reasonable to assume that
the hepatic excretion of octreotide varies accord-
ing to the severity of the liver disease, a hypo-
thesis supported by the findings of the present
study. Further support for this suggestion
is provided by the finding that half of the
dosage of octreotide resulted in almost identical
arterial concentrations of the analogue in cirrho-
tic patients compared to the levels observed
in normal healthy controls after a full dose [6].
Further studies are,. however, required to fully
establish the relationship between the degree of
hepatic dysfunction and the plasma half-life of
octreotide.
The six patients who participated in the
pharmacokinetic part of this study had been
receiving 50 tg of octreotide s.c.b.d, for 4 weeks
prior to investigation. In all these patients
appreciable levels of octreotide were present
in the baseline blood samples, i.e., 12 h after the
last injection of the analogue prior to the study.
Furthermore, the highest plasma levels were
observed in those with moderate (Child’s B) or
severe (Child’s C) liver disease. These observa-
tions suggest that even with a relatively low
dosage regime, i.e., 50 tg octreotide s.c.b.d, there
is accumulation of the analogue in the blood,
particularly in patients with moderate or severe
liver disease, presumably as a result of the
increase in the plasma half-life. These observa-
tions have obvious implications for the there
apeutic use of octreotide in cirrhotic patients.
Thus, particularly during prolonged periods of
administration in cirrhotic patients, dosage regi-
mens should be modified to avoid accumulation
of octreotide in the blood which may result in
undersirable side-effects or toxicity.
Intravenous bolus administrations of either
250 tg somatostatin or 50 tg octreotide resulted
in a significant decrease in wedged and cor-
rected wedged hepatic venous pressures. These
results are therefore in accord with previous
observations indicating that intravenous admin-
istration of both somatostatin and octreotide and
subcutaneous administration of the analogue
decrease portal pressure [7-14]. However, it
should be pointed out that other reports sug-
gests that octreotide and somatostatin have no
effect on corrected WHVP in portal hypertensive
patients [15-17]. These conflicting observations
on the effects of somatostatin and octreotide
on corrected WHVP are difficult to reconcile but
may be related to the amount given, the mode
of administration and the severity of the portal
hypertension. Nevertheless, the consensus of
opinion is that both somatostatin and octreotide
reduce corrected WHVP in cirrhotic patients by
eliciting a splanchnic vasoconstriction thereby
reducing portal flow and portal pressure [18].
The increase in arterial blood pressure and
decrease in heart rate elicited by both octreotide
and somatostatin in the present study occurred
after the wedged and corrected wedged hepatic
venous pressures began to decrease suggestingPHARMACOKINETICS OF OCTREOTIDE 19
that they may be secondary reflex responses to
compensate for the increase in splanchnic
vasoconstriction.
The precise mechanism whereby somatostatin
and octreotide elicit splanchnic vasoconstriction
is not known. The rapidity of onset of the
reduction in corrected WHVP following soma-
tostatin or octreotide administration supports
the suggestion that both compounds act directly
on receptors on the smooth muscle of the
splanchnic vasculature [19]. Alternatively, so-
matostatin and octreotide may elicit vasocon-
striction by inhibiting the release and end-organ
action of vasoactive substances responsible
for maintaining the hyperdynamic circulation
in portal hypertensive patients. Clearly, further
work is required to establish more precisely the
mechanism of action of somatostatin and octreo-
tide on hepatic and splanchnic haemodynamics.
Nevertheless, irrespective of their mode of
action, the reduction in portal venous inflow,
portal pressure and azygos blood flow second-
ary to splanchnic vasoconstriction is presumed
to be mechanism whereby both drugs are effec-
tive in controlling the acute variceal bleed.
In the present study a bolus injection of 250
somatostatin or 50 tg octreotide elicited a reduc-
tion in corrected WHVP of approximately the
same magnitude. Furthermore, the duration of
the response to octreotide was not significantly
greater than that elicited by somatostatin,
despite the presence of appreciable amounts of
the analogue in the blood I h after administra-
tion. The short duration of action of octreotide
on WHVP was perhaps surprising since other
effects of the analogue such as the suppression
of growth hormone or.growth hormone releas-
ing factor are prolonged and proportional to
the blood levels [20]. However, it is now evident
that there are a family of receptors that bind
somastostatin and octreotide with different
binding affinities [21, 22, 23]. Furthermore, the
somatostatin receptor sub-types have variable
but specific structural requirements to facilitate
binding with either somatostatin or its analo-
gues [21, 22,23]. Differences in the somatostatin
receptor sub-type responsible for a specific
action of somatostatin would offer an explana-
tion for differences between the pharmacody-
namic characteristics of octreotide with respect
to its effect on growth hormone and insulin
release [24]. Thus, after a single dose of
octreotide in rhesus monkeys, the inhibition of
growth hormone release persists for much
longer periods than that of insulin [24]. The
somatostatin receptors in gastrointestinal tissue
appear to consist of at least two subtypes viz.
high affinity receptors similar to those found
in the cerebral cortex and low affinity, high
capacity subtypes to which analogues such as
octreotide bind poorly or not at all [23]. If these
low affinity somatostatin receptors are involved
in the events leading to a reduction in corrected
WHVP by somatostatin or octreotide, the low
binding of the analogue to such sites would offer
an explanation for the relatively short duration
of response. However, this hypothesis requires
confirmation by identification of the somatosta-
tin receptor subtypes involved in reducing
WHVP. Nevertheless, regardless of the mechan-
isms involved, the results of this study clearly
suggest that in terms of reducing portal pres-
sure, octreotide is not long-acting and requires
intravenous administration to produce a sus-
tained decrease in portal pressure. This sugges-
tion is supported by the results of clinical trials
on the efficacy of octreotide in controlling acute
variceal bleeding. Thus, one such trial reported
that intravenous administration of octreotide
(25 tg/h) was more efficacious than glypressin
plus nitroglycerin (86% and 62% respectively)
in controlling bleeding over a 12 h period [25].
Over the next 36 h of the trial during which
octreotide was given subcutaneously, more
patients in the analogue-treated group experi-
enced rebleeding than in the glypressin-nytro-
glycerin group so that the overall control of
bleeding was not significantly different between
the 2 groups over the 48 h assessment period
(55% and 48% overall control of bleeding20 S.A. JENKINS et al.
respectively) [25]. In contrast, two trials have
reported that intravenous octreotide is as good
as one course of injection sclerotherapy in control-
ling variceal bleeding and preventing recurrence
over a 48 h trial period [26- 27].
In summary, the results of this study indicate
that the plasma half-life of octreotide in cirrhotic
patients is prolonged, presumably as a result of
diminished hepatic excretion. However, in terms
ofreducing portal pressure, the duration of action
of octreotide is not significantly longer than that
of somatostatin. Consequently, like somatostatin,
octreotide has to be administered intravenously
to produce a sustained response and hence a
therapeutic effect in the management of the
acute variceal bleed.
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